Citicoline (CDP-Choline)
NootropicThe small divergence between the medical score (72) [s5, s6, s7, s8] and the community score (68) [c1, c2] reflects broad agreement: positive cognitive effects are both clinically established and observed in the community, albeit with limitations from large negative stroke/TBI trials [s7, s8] and mixed user experiences [c1, c4].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Citicolin is among the better-studied nootropics: positive RCT data for memory and cognition in healthy older adults and MCI patients stand against negative results in large stroke and TBI trials — meaning the benefit is clearly population-dependent. Tolerability is good at 250–500 mg/day; higher doses, especially combined with Alpha-GPC, are associated with depressive mood and vivid dreams. No longer approved as a pharmaceutical in Germany, but available OTC as a supplement. For healthy adults seeking cognitive support, Citicolin is one of the more evidence-backed options in the nootropic space.
Description
Citicoline (CDP-choline) is a naturally occurring nucleotide intermediate that promotes phosphatidylcholine synthesis, modulates neurotransmitters, and exhibits neuroprotective effects [s1, s2].
Citicoline (cytidine-5'-diphosphocholine, CDP-choline) is an endogenous intermediate in the Kennedy metabolic pathway, present in all human cells. Following oral administration, citicoline is hydrolyzed in the intestine and liver into cytidine and choline [s3]. Both metabolites efficiently cross the blood-brain barrier and are resynthesized into citicoline in the brain [s3, s4]. As a dietary supplement, citicoline is primarily used for cognitive support. In a double-blind, placebo-controlled RCT in healthy older adults (n=100), supplementation with 500 mg/day citicoline for 12 weeks demonstrated significant improvements in episodic memory (Paired Associates Test) compared to placebo [s5]. As a pharmaceutical, citicoline was used for decades in stroke and other cerebrovascular diseases. However, a large-scale RCT (ICTUS trial, n=2298) showed no significant superiority over placebo in acute ischemic stroke [s7]. The COBRIT trial (n=1213) likewise found no significant benefit in traumatic brain injury [s8]. More recent network meta-analyses suggest that citicoline at certain doses (750–2000 mg/day) may improve neurological recovery after ischemic stroke, though the optimal dose remains under discussion [s9]. In mild cognitive impairment (MCI), a systematic review and meta-analysis shows positive effects on cognitive function [s6]. In Germany, pharmaceutical approvals for citicoline are no longer active; the substance is marketed exclusively as a dietary supplement [s15].
Legal Status (DE)
In Germany, pharmaceutical products containing citicoline are currently (as of 2024) no longer approved. However, the substance is freely marketable as an over-the-counter dietary supplement [s15]. The European Commission has approved citicoline as an ingredient for dietary supplements [s14]. In the United States, citicoline is classified as GRAS (Generally Recognized As Safe) for use as a food ingredient [s13].
Mechanism of Action
Citicoline acts through several complementary mechanisms: 1. Phosphatidylcholine synthesis: Citicoline is a central intermediate in the Kennedy pathway and increases the synthesis of phosphatidylcholine, the primary component of neuronal cell membranes. This supports membrane integrity and repair following ischemic or traumatic injury [s1, s4]. 2. Acetylcholine synthesis: The released choline serves as a precursor for acetylcholine synthesis. Since the brain preferentially utilizes choline for neurotransmitter synthesis, exogenous citicoline can support both acetylcholine and phosphatidylcholine synthesis in parallel [s4]. 3. Catecholaminergic modulation: Citicoline increases dopamine and noradrenaline levels in the CNS by modulating catecholaminergic neurotransmission. Serotonin concentrations are likewise elevated [s10, s11]. 4. Neuroprotective effects: Following ischemic events, citicoline exerts anti-excitatory, antioxidant, membrane-stabilizing, and regenerative effects. It inhibits the release of free fatty acids from ischemically damaged neurons and reduces glutamate-mediated excitotoxicity [s1, s12]. 5. Dopamine receptor density: Animal studies and mechanistic data suggest that CDP-choline increases dopamine receptor density, potentially contributing to cognitive improvement [s10]. Orally administered citicoline is well absorbed and demonstrates high bioavailability; it is effective both orally and intravenously [s3].
Dosing
Kognitive Verbesserung bei gesunden Erwachsenen
- Dose
- 500 mg citicoline
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 12 Wochen oder fortlaufend
- Timing
- Morning with breakfast
- With food
- empfohlen
Leichte kognitive Beeinträchtigung (MCI)
- Dose
- 500–1000 mg citicoline
- Frequency
- 1× täglich oder aufgeteilt
- Route
- oral
- Duration
- 12–24 Wochen
- Timing
- Morning, optionally split
- With food
- empfohlen
Neuroprotektive Unterstützung / Schlaganfall-Nachsorge (klinisch, nicht als NEM)
- Dose
- 500–2000 mg citicoline
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- 6 Wochen bis mehrere Monate
- Timing
- Under medical supervision
- With food
- empfohlen
In clinical trials, doses up to 2000 mg/day have been used [s7]. Doses exceeding 2000 mg/day may cause adverse effects such as GI complaints, headache, and tachycardia [s16]. Typical dosages for dietary supplements are 250–500 mg/day.
Citicoline is available over the counter as a dietary supplement in Germany. High-dose use (>500 mg/day) should be discussed with a physician. Individuals with bipolar disorder should avoid citicoline [s16].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Durchfall, Magenbeschwerden) Documented as an occasional adverse effect in clinical trials [s16, s2]. | gelegentlich | leicht |
| Vorübergehende Kopfschmerzen Described in clinical trials and case reports [s16]. | gelegentlich | leicht |
| Hypotonie oder Blutdruckveränderungen Rarely reported in clinical studies [s16]. | selten | leicht |
| Tachykardie oder Bradykardie Rare cardiovascular adverse effects documented in clinical studies [s16]. | selten | moderat |
| Innere Unruhe / Agitation Described as a possible adverse effect at higher doses [s16]. | selten | leicht |
| Intensive oder ungewöhnliche Träume Frequently mentioned in community reports, possibly due to increased acetylcholine synthesis [c1, c3]. | gelegentlich | leicht |
| Depressive Verstimmung bei Überversorgung mit Cholin Reported in community accounts, particularly in combination with Alpha-GPC or at high doses [c1]. | selten | moderat |
Contraindications
Citicoline may exacerbate manic episodes; use in bipolar disorder should be avoided [s16].
As with all substances, use should be avoided in cases of known hypersensitivity.
Insufficient safety data available for pregnancy/lactation; use not recommended [s16].
Interactions
Synergistic
Classic combination in the nootropic community; racetams increase choline demand, which citicoline can meet. Mechanistically plausible, but clinical RCT data are lacking.
Citicoline provides cytidine as a precursor for uridine; synergistic effects on membrane synthesis and cognitive substrate are possible [s3].
Alpha-GPC provides rapidly available choline for acetylcholine synthesis, while citicoline repairs cell membranes and offers sustained cognitive support. The combination may produce synergistic effects on memory, focus, and neuroprotection. Total daily choline intake should not exceed 3,500 mg.
Both substances protect neurons from oxidative stress and support mitochondrial function. ALCAR enhances acetylcholine status, complementing the cholinergic effect of citicoline. A typical combination is 500–1000 mg ALCAR with 250–500 mg citicoline.
Bacopa inhibits acetylcholinesterase and activates choline acetyltransferase, complementing the cholinergic action of citicoline. Both substances exert antioxidant neuroprotective effects and support memory and cognitive function. This combination has been clinically investigated as a metabolic correction in cognitive impairment.
Citicoline provides cytidine as a uridine precursor, which together with DHA from omega-3 and choline promotes phosphatidylcholine synthesis for neuronal membranes. This combination supports synaptic formation and neuronal repair. Mechanistically known as the "Kennedy cycle stack."
Caution
Citicoline raises dopamine levels; theoretically additive effects are possible. Caution when combining with dopaminergic medications [s10].
Additive cholinergic effects via increased acetylcholine synthesis; overdose is possible [s4].
Antagonistic effect on cholinergic neurotransmission; combination reduces the efficacy of both substances [s4].
Combining both cholinergic substances increases the risk of choline overload at high doses. Symptoms may include fatigue, headache, and excessive sweating. Total daily choline intake should not exceed 3,500 mg.
Studies
Tier A — High Evidence
Outcome: Cognitive function (Computerized Memory Battery) in healthy older adults
Effect Size: Significant improvement in episodic memory (Paired Associates, p<0.00625) and composite memory
Outcome: Cognitive function and dementia prevention in MCI/dementia
Effect Size: Positive effects on cognition in MCI; heterogeneous study landscape
Outcome: Functional and cognitive outcomes following traumatic brain injury (TBI-CNS Core Battery)
Effect Size: No significant difference vs. placebo on any of the 9 scales
Outcome: Neurological prognosis in acute ischemic stroke by dosage
Effect Size: Citicoline 750–2000 mg/day showed a trend toward improved neurological outcomes; optimal dose unclear
Outcome: Composite of NIHSS, modified Rankin Scale, and Barthel Index in acute ischemic stroke
Effect Size: No significant difference between citicoline 2000 mg/day and placebo
Tier B — Moderate Evidence
Outcome: Pharmacokinetics, bioavailability, and clinical application of citicoline
Effect Size: High oral bioavailability confirmed; cleavage into cytidine and choline documented
Outcome: Use of citicoline in mild cognitive impairment
Effect Size: Positive indications of cognitive support; mechanistic basis described
Tier C — Low Evidence
Outcome: Citicoline in substance use disorders (cocaine, alcohol)
Effect Size: Preliminary positive signals; only small pilot studies available
Community Evidence
Top reported benefits
- Improved mental clarity and focus
- Better memory and learning ability
- Increased mental energy without stimulant sensation
- Good tolerability at low doses (250–500 mg)
Top reported issues
- Intense, sometimes frightening dreams in some users
- Depressive mood at high doses or in combination with Alpha-GPC
- No noticeable effect in some users
- Higher cost compared to Alpha-GPC
Some users on r/Nootropics report vivid nightmares and sleep disturbances [c3]. The combination of citicoline with Alpha-GPC has been associated with depressive mood due to possible choline overload [c1]. German forums (AMSEL) contain isolated reports of lack of efficacy, particularly in MS patients [c4]. Overall, the data from the German-speaking community is limited.
Scientific Sources
- Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues
Secades JJ, Frontera G (2014). CNS & Neurological Disorders - Drug TargetsBPMID:24588994DOI - Role of Citicoline in Patients With Mild Cognitive Impairment
Bermejo PE, Dorado R, Zea-Sevilla MA (2023). Neurology and TherapyBPMID:36930385DOI - Citicoline for Supporting Memory in Aging Humans
Jasielski P, Piedel F, Piekut T, et al. (2023). NutrientsBDOI - Citicoline in Addictive Disorders: A Review of the Literature
Yoon SJ, Lyoo IK, Haws C, et al. (2010). The American Journal on AddictionsBPMID:20716310DOI - Lifewe's CitiCogni Citicoline and Citicoline Sodium were Granted SELF-GRAS
Witspower (Lifewe) (2024). Witspower Industry NewsBLink - Durchführungsbeschluss der Kommission zur Genehmigung des Inverkehrbringens von Citicolin als neuartige Lebensmittelzutat
Europäische Kommission (2014). Amtsblatt der Europäischen UnionALink - Citicholin - DocCheck Flexikon
DocCheck Medical Services GmbH (2024). DocCheck FlexikonBLink - Citicolin und Citicolin-Natrium: Der umfassende Leitfaden
OCTAGONCHEM (2024). OCTAGONCHEM BlogCLink - CDP-Cholin ohne Wirkung bei Schlaganfall und Schädelhirntrauma
Deutsches Ärzteblatt (2013). Deutsches ÄrzteblattBLink - Cognizin Citicoline — Self-Affirmed GRAS Determination (Kyowa Hakko USA, 2009)
Kyowa Hakko USA, Inc. (2009). BLink - CDP-choline: pharmacological and clinical review
Secades JJ, Lorenzo JL (1995). Methods and Findings in Experimental and Clinical PharmacologyBPMID:8709678 - The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives
Gareri P, Castagna A, Cotroneo AM, et al. (2015). Journal of Neurology ResearchBPMID:26029771DOI - Citicoline in Addictive Disorders: A Review of the Literature
Yoon SJ, Lyoo IK, Haws C, et al. (2010). The American Journal on AddictionsBPMID:20716310DOI - Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Nakazaki E, Mah E, Sanoshy K, et al. (2021). The Journal of NutritionAPMID:33978188DOI - Is Citicoline Effective in Preventing and Slowing Down Dementia?—A Systematic Review and a Meta-Analysis
Jasielski P, Piedel F, Piekut T, et al. (2023). NutrientsAPMID:36678178DOI - Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)
Dávalos A, Alvarez-Sabín J, Castillo J, et al. (2012). The LancetAPMID:22738577DOI - Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT)
Zafonte RD, Bagiella E, Ansel BM, et al. (2012). JAMAAPMID:23168823DOI - The efficacy of different doses of citicoline in improving the prognosis of patients with acute ischemic stroke based on network meta-analysis
Chen Y, Zhao L, Zhang Y, et al. (2025). Frontiers in PharmacologyADOI
Community Sources
Storage
Unopened
Store in a cool, dry, light-protected location; room temperature (15–25 °C).
Opened
Keep container tightly closed; avoid moisture and direct sunlight.
Notes
Citicoline is hygroscopic; powder forms should be particularly protected from moisture absorption.